What the business is, and whether it's a good one at a fair price.
Manufactures Active Pharmaceutical Ingredients (APIs) as its sole business segment, reporting FY26 revenue of Rs. 103.66 crore and net profit of Rs. 13.11 crore. The cost structure is led by raw materials and inputs at 41.2% of revenue, followed by other operating expenses at 35.7%, employee costs at 5.9% and depreciation at 3.6%, with capex at 1.9% of revenue. The standalone company has no subsidiaries, associates or joint ventures, ran with zero borrowings and held cash and equivalents of Rs. 4,184.29 lakh at FY26 year-end, alongside trade receivables of Rs. 1,671.41 lakh. Q4 FY26 total income fell to Rs. 1,961.08 lakh from Rs. 2,933.95 lakh in the preceding quarter, with Q4 net profit of Rs. 85.36 lakh. SEBI issued an ex-parte interim order and a confirmatory order restraining a proposed slump sale of the primary business to a related party; the company is evaluating legal remedies.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from PAR DRUGS AND CHEM LTD's filed financials and exchange disclosures
PAR DRUGS AND CHEM LTD is a Pharmaceuticals & Biotechnology company listed on NSE, trading under the symbol PAR.
Yes. Over the trailing twelve months PAR DRUGS AND CHEM LTD reported a net profit of ₹14 Cr on revenue of ₹109 Cr.
Not in the latest reported year — PAR DRUGS AND CHEM LTD's dividend payout for FY26 was nil.
Effectively yes. It holds ₹42 Cr more cash than debt. Debt stands at 0.00× equity.
On trailing P/E, PAR DRUGS AND CHEM LTD ranks 28 of 169 in Pharmaceuticals — cheaper than 84% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session PAR DRUGS AND CHEM LTD moves 1.61% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by PAR DRUGS AND CHEM LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
